Prostate Cancer P D:SPINK1表达在非裔美国人前列腺中富集并且与术后免疫浸润或者肿瘤结果无关

2019-03-23 AlexYang MedSci原创

SPINK1分子亚型在非裔美国人(AA)前列腺恶性肿瘤(PCa)中要比欧裔美国人(EA)更为常见。有研究表明SPINK1表达与更富侵略性的疾病相关。然而,先前患者群体的大小、跟踪调查情况和种族差异限制了对SPINK1在AA男性中表达的理解。最近,有研究人员确定了根治性前列腺切除术(RP)后SPINK1亚型与种族和肿瘤结果的相关性。研究包括了经历了RP的186名AA和206名EA男性,并根据病理等级

SPINK1分子亚型在非裔美国人(AA)前列腺恶性肿瘤(PCa)中要比欧裔美国人(EA)更为常见。有研究表明SPINK1表达与更富侵略性的疾病相关。然而,先前患者群体的大小、跟踪调查情况和种族差异限制了对SPINK1在AA男性中表达的理解。最近,有研究人员确定了根治性前列腺切除术(RP)后SPINK1亚型与种族和肿瘤结果的相关性。

研究包括了经历了RP的186名AA和206名EA男性,并根据病理等级进行匹配。研究发现,在AA男性和EA男性中,SPINK1阳性亚型占比分别为25% (45/186)和15% (30/206)。在SPINK1阳性和SPINK1阴性肿瘤对比或者种族对比中,病理等级、病理阶段、无生化复发生存或者无转移生存均没有差异。多变量分析表明了无论在AA男性或者EA男性中,SPINK1表达与BCR(AA: HR 0.99, 95% CI 0.56-1.75, p=0.976; EA: HR 0.88, 95% CI 0.43-1.77, p=0.720)和转移(AA: HR 0.79, 95% CI 0.25-02.49, p=0.691; EA: HR 1.55, 95% CI 0.58-4.11, p=0.381)不相关。另外,在SPINK1阳性和阴性肿瘤或者不同的种族中, 周围CD3/CD8淋巴细胞密度也没有显著的差异。

最后,研究人员指出,SPINK1阳性亚型在PCa AA男性中要比EA男性更加常见。与之前的研究不同,他们发现无论在AA男性或者EA男性中,SPINK1蛋白的表达在RP后与更差的病理或者肿瘤结果不相关。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977400, encodeId=c4f419e7400a1, content=<a href='/topic/show?id=43d214294b7' target=_blank style='color:#2F92EE;'>#PINK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14294, encryptionId=43d214294b7, topicName=PINK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Feb 25 20:09:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791572, encodeId=4eff1e915721e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 01 18:09:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910813, encodeId=6f64191081342, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 09 23:09:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819646, encodeId=e5471819646b8, content=<a href='/topic/show?id=12a1996e84b' target=_blank style='color:#2F92EE;'>#非裔美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99678, encryptionId=12a1996e84b, topicName=非裔美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Aug 18 09:09:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364472, encodeId=32b913644e25f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557308, encodeId=561d155e308b7, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602135, encodeId=1a9f1602135c6, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2020-02-25 minzju5052
  2. [GetPortalCommentsPageByObjectIdResponse(id=1977400, encodeId=c4f419e7400a1, content=<a href='/topic/show?id=43d214294b7' target=_blank style='color:#2F92EE;'>#PINK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14294, encryptionId=43d214294b7, topicName=PINK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Feb 25 20:09:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791572, encodeId=4eff1e915721e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 01 18:09:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910813, encodeId=6f64191081342, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 09 23:09:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819646, encodeId=e5471819646b8, content=<a href='/topic/show?id=12a1996e84b' target=_blank style='color:#2F92EE;'>#非裔美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99678, encryptionId=12a1996e84b, topicName=非裔美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Aug 18 09:09:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364472, encodeId=32b913644e25f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557308, encodeId=561d155e308b7, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602135, encodeId=1a9f1602135c6, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1977400, encodeId=c4f419e7400a1, content=<a href='/topic/show?id=43d214294b7' target=_blank style='color:#2F92EE;'>#PINK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14294, encryptionId=43d214294b7, topicName=PINK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Feb 25 20:09:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791572, encodeId=4eff1e915721e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 01 18:09:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910813, encodeId=6f64191081342, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 09 23:09:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819646, encodeId=e5471819646b8, content=<a href='/topic/show?id=12a1996e84b' target=_blank style='color:#2F92EE;'>#非裔美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99678, encryptionId=12a1996e84b, topicName=非裔美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Aug 18 09:09:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364472, encodeId=32b913644e25f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557308, encodeId=561d155e308b7, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602135, encodeId=1a9f1602135c6, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1977400, encodeId=c4f419e7400a1, content=<a href='/topic/show?id=43d214294b7' target=_blank style='color:#2F92EE;'>#PINK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14294, encryptionId=43d214294b7, topicName=PINK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Feb 25 20:09:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791572, encodeId=4eff1e915721e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 01 18:09:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910813, encodeId=6f64191081342, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 09 23:09:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819646, encodeId=e5471819646b8, content=<a href='/topic/show?id=12a1996e84b' target=_blank style='color:#2F92EE;'>#非裔美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99678, encryptionId=12a1996e84b, topicName=非裔美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Aug 18 09:09:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364472, encodeId=32b913644e25f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557308, encodeId=561d155e308b7, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602135, encodeId=1a9f1602135c6, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1977400, encodeId=c4f419e7400a1, content=<a href='/topic/show?id=43d214294b7' target=_blank style='color:#2F92EE;'>#PINK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14294, encryptionId=43d214294b7, topicName=PINK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Feb 25 20:09:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791572, encodeId=4eff1e915721e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 01 18:09:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910813, encodeId=6f64191081342, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 09 23:09:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819646, encodeId=e5471819646b8, content=<a href='/topic/show?id=12a1996e84b' target=_blank style='color:#2F92EE;'>#非裔美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99678, encryptionId=12a1996e84b, topicName=非裔美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Aug 18 09:09:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364472, encodeId=32b913644e25f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557308, encodeId=561d155e308b7, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602135, encodeId=1a9f1602135c6, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-03-25 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1977400, encodeId=c4f419e7400a1, content=<a href='/topic/show?id=43d214294b7' target=_blank style='color:#2F92EE;'>#PINK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14294, encryptionId=43d214294b7, topicName=PINK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Feb 25 20:09:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791572, encodeId=4eff1e915721e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 01 18:09:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910813, encodeId=6f64191081342, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 09 23:09:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819646, encodeId=e5471819646b8, content=<a href='/topic/show?id=12a1996e84b' target=_blank style='color:#2F92EE;'>#非裔美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99678, encryptionId=12a1996e84b, topicName=非裔美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Aug 18 09:09:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364472, encodeId=32b913644e25f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557308, encodeId=561d155e308b7, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602135, encodeId=1a9f1602135c6, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1977400, encodeId=c4f419e7400a1, content=<a href='/topic/show?id=43d214294b7' target=_blank style='color:#2F92EE;'>#PINK1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14294, encryptionId=43d214294b7, topicName=PINK1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Feb 25 20:09:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791572, encodeId=4eff1e915721e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 01 18:09:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910813, encodeId=6f64191081342, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 09 23:09:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819646, encodeId=e5471819646b8, content=<a href='/topic/show?id=12a1996e84b' target=_blank style='color:#2F92EE;'>#非裔美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99678, encryptionId=12a1996e84b, topicName=非裔美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Sun Aug 18 09:09:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364472, encodeId=32b913644e25f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557308, encodeId=561d155e308b7, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602135, encodeId=1a9f1602135c6, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Mar 25 04:09:00 CST 2019, time=2019-03-25, status=1, ipAttribution=)]
    2019-03-25 zhaojie88

相关资讯

Sci Rep:p300/CBP相关的因子能够促进δ-连环蛋白的自噬降解和减少前列腺癌的致瘤性

δ-连环蛋白与β-连环蛋白具有共同的结合分子。因为乙酰化和去乙酰化能够调控β-连环蛋白的稳定性,最近,研究人员探寻了组蛋白乙酰转移酶(HATs)或者组蛋白去乙酰化酶(HDACs)在影响δ-连环蛋白乙酰化状态和蛋白水平方面的情况。研究人员发现,p300/CBP相关的因子(PCAF)能够直接结合乙酰化δ-连环蛋白,然而一些I类和II类HDACs能够恢复上述影响。与β-连环蛋白不同,δ-连环蛋白能够通过

Oncogene:MicroRNA-1205与去势难治性前列腺癌风险有关

染色体8q24.21位点包含了原癌基因c-MYC、长非编码RNA PVT1和microRNAs(miRs),是人类前列腺癌中最常见的扩增区域。遗传变异与该位点的c-MYC和长非编码RNA PVT1长期互作能够导致前列腺癌的遗传风险。在该位点包含6个miRs(miR-1204, -1205, -1206, -1207-3p, -1207-5p和-1208),但是他们的功能仍旧未知。最近,有研究人员利

Oncogenesis:二氢青蒿素能够通过JARID2/miR-7/miR-34a依赖的Axl下调来抑制前列腺癌

Axl的表达在一些癌症类型中不受调控,并且能够预测不良总患者生存,且与药物治疗抗性的产生有关。最近,有研究人员评估了Axl天然化合物抑制剂库,鉴定了二氢青蒿素(有效成分为抗疟疾药物青蒿素)可以作为前列腺癌中Axl的抑制剂。研究发现,二氢青蒿素能够阻断Axl的表达从而导致细胞凋亡,减少前列腺癌细胞的细胞增殖、迁移和肿瘤发生。多烯紫杉醇是转移性前列腺癌的标准治疗药物,能够增加人类异种种植小鼠模型的总生

Prostate Cancer P D:MRI-US融合前列腺活检学习曲线鉴定分析

MRI-US融合前列腺活检在诊断前列腺癌中已经成为一种常见的步骤。考虑到融合活检的学习曲线,仍旧缺乏相关信息。最近,有研究人员研究了在该步骤中能够准确和有效进行时需要的经验量。研究人员前瞻性的搜集了MRI-US融合活检的患者数据,这些融合活检在2014年4月到2017年8月之间进行。研究人员利用2个参数来定义学习曲线,即效率和准确度。之后,他们利用图形和数学的方法来确定学习曲线。研究人员为完成了7

Nucleic Acids Res:揭示长链非编码RNA PCAT1促进去势抵抗性前列腺癌进展的新机制

近期,天津医科大学第二医院牛远杰教授、尚芝群副教授课题组最新报道了长链非编码RNA PCAT1通过调控PHLPP/FKBP51/IKKα蛋白复合体,同时增强AKT和NF-κB两条信号通路,促进去势抵抗性前列腺癌进展中的作用机制。相关研究成果于2019年2月在线发表在权威期刊《Nucleic Acids Res》,题目为“LncRNA PCAT1 activates AKT and NF-κB si

Prostate Cancer P D:MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标

转移去势抵抗性前列腺癌(mCRPC)目前难以治愈,以雄激素受体信号为靶标的药物治疗后的恶化也难以避免。因此,除了激素治疗手段外,开发更多有效的治疗方法非常迫切。最近,有研究人员鉴定了已经存在药物和改善过的药物对mCRPC中激活的激酶作为治疗靶标的可能性,目的在于鉴定候选药物从而实现快速将其进入mCRPC概念验证第二阶段试验。研究包括了101名患有mCRPC的患者。研究人员将这101名mCRPC患者